SAVA icon

Cassava Sciences

1.70 USD
-0.05
2.86%
At close Mar 27, 4:00 PM EDT
Pre-market
1.69
-0.01
0.59%
1 day
-2.86%
5 days
-37.27%
1 month
-34.62%
3 months
-32.00%
6 months
-94.03%
Year to date
-38.18%
1 year
-91.67%
5 years
-44.08%
10 years
-81.32%
0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

6.87% more ownership

Funds ownership: 29.27% [Q3] → 36.13% (+6.87%) [Q4]

14% less funds holding

Funds holding: 160 [Q3] → 137 (-23) [Q4]

38% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 52

63% less call options, than puts

Call options by funds: $10.1M | Put options by funds: $27.2M

87% less capital invested

Capital invested by funds: $412M [Q3] → $51.8M (-$360M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$2
18%
upside
Avg. target
$2
18%
upside
High target
$2
18%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
HC Wainwright & Co.
Vernon Bernardino
24% 1-year accuracy
16 / 67 met price target
18%upside
$2
Neutral
Reiterated
25 Mar 2025

Financial journalist opinion

Based on 6 articles about SAVA published over the past 30 days

Negative
Reuters
1 day ago
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam.
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
Negative
Zacks Investment Research
2 days ago
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Negative
Benzinga
2 days ago
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences Inc. SAVA on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Neutral
GlobeNewsWire
3 days ago
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy, today shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD.
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Positive
Zacks Investment Research
2 weeks ago
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
GlobeNewsWire
3 weeks ago
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures, today reported financial results for the year ended December 31, 2024 and provided a business update.
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Neutral
Accesswire
1 month ago
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128597&wire=1 or contact Joseph E. Levi, Esq.
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Neutral
Accesswire
1 month ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128562&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
Neutral
Accesswire
1 month ago
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128534&wire=1 or contact Joseph E. Levi, Esq.
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
Neutral
Accesswire
1 month ago
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128502&wire=1 or contact Joseph E. Levi, Esq.
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Charts implemented using Lightweight Charts™